title: Intercellular adhesion molecule-1 on cultured human melanoma cells: influence of cytokines.
abstract: Adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and its counter-receptor, lymphocyte function associated antigen-1 (LFA-1), play very important roles in immune responses. In this study, the effects of cytokines on cultured human melanoma cells (MMG2) were examined, especially focussing on the expression of ICAM-1 on MMG2 and lymphocyte adhesion to MMG2. Both the expression of ICAM-1 and HLA-DR on MMG2 increased after treatment with IFN-gamma. ICAM-1 expression began to increase earlier than HLA-DR expression. TNF-alpha and IL-1 beta also increased the expression of ICAM-1 on MMG2. However, these cytokines did not increase the expression of HLA-DR. IFN-gamma had a dose dependent effect on lymphocyte adhesion to MMG2. Pretreatment of IFN-gamma treated MMG2 with 84H10 (anti-ICAM-1 antibody) or pretreatment of lymphocytes with either SPV-L7 (anti-LFA-1 alpha antibody) or IOT10 (anti-LFA-1 beta antibody) inhibited the lymphocyte adhesion to MMG2. These results suggest that ICAM-1 molecules induced on melanoma cells by IFN-gamma can interact with LFA-1 molecules on lymphocytes.
authors.affiliation: Department of Dermatology, Gifu University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yoneda
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: M
authors.initials: M
authors.lastname: Takemura
authors.forename: A
authors.initials: A
authors.lastname: Noma
authors.forename: A
authors.initials: A
authors.lastname: Yamamoto
mesh_terms: D015703:Antigens, CD / Q000032:analysis* / Q000235:genetics; D002448:Cell Adhesion / Q000187:drug effects; D015815:Cell Adhesion Molecules / Q000032:analysis* / Q000235:genetics; D016207:Cytokines / Q000494:pharmacology*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D015870:Gene Expression / Q000187:drug effects; D006684:HLA-DR Antigens / Q000032:analysis / Q000235:genetics; D006801:Humans; D018799:Intercellular Adhesion Molecule-1; D007370:Interferon Type I / Q000494:pharmacology; D016899:Interferon-beta / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D016169:Lymphocyte Function-Associated Antigen-1 / Q000494:pharmacology; D008214:Lymphocytes / Q000473:pathology; D008545:Melanoma / Q000473:pathology*; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000473:pathology*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D015703:Antigens, CD; D015815:Cell Adhesion Molecules; D016207:Cytokines; D006684:HLA-DR Antigens; D007370:Interferon Type I; D007375:Interleukin-1; D007376:Interleukin-2; D016169:Lymphocyte Function-Associated Antigen-1; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; D016899:Interferon-beta; D007371:Interferon-gamma